ArticleKidney diseases (Basel, Switzerland)
Application of Surface-Enhanced Raman Spectroscopy and Machine Learning Omics Techniques in the Progression Assessment of Autosomal Dominant Polycystic Kidney Disease.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The progression evaluation of autosomal dominant polycystic kidney disease (ADPKD) is critical to the treatment strategy and prognosis prediction of the disease, but the current evaluation methods are time-consuming and costly. Methods: ADPKD patients were recruited in Shanghai Changzheng Hospital from February 2023 to October 2023. Based on the Mayo imaging classification (MIC) model, patients with different disease progression rates were classified into slowly progressive (SP) group (MIC 1A, 1B) or rapidly progressive (RP) group (MIC 1C, 1D, and 1E). The Raman spectra of urine samples from ADPKD patients were obtained by Surface-enhanced Raman spectroscopy (SERS) protocol and the characteristics of urine Raman spectra from SP and RP groups were analyzed. The ADPKD progression prediction model was constructed based on principal component analysis (PCA) and support vector machine (SVM). Results: After adjusting for age, gender, and renal function, there were differences in Raman intensity of the six major Raman peaks (758/794/1,184/1,288/1,346/1,385 cm Conclusions: Urinary SERS detection can distinguish RP ADPKD patients from SP ones noninvasively, conveniently and quickly, with reasonable accuracy, sensitivity, and specificity. SERS combined with machine learning omics techniques might be a novel method to evaluate the progression of ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.